C4 Therapeutics, Inc. (CCCC) stock
CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/302% below fair value
$2.48−0.05 (-2.17%)
Close on Nov 18, 2026Market cap $304.49MP/E –Yield –
C4 Therapeutics net income
Net income is the profit left for shareholders after every expense, interest and tax.
C4 Therapeutics's net income for the twelve months ending Jun 30, 2026 was -$101.42M. For fiscal 2025 it was -$104.99M. The highest annual figure on record is -$34.10M in fiscal 2019.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$104.99M | – |
| FY2024 | Dec 31, 2024 | -$105.32M | – |
| FY2023 | Dec 31, 2023 | -$132.49M | – |
| FY2022 | Dec 31, 2022 | -$128.18M | – |
| FY2021 | Dec 31, 2021 | -$83.89M | – |
| FY2020 | Dec 31, 2020 | -$66.34M | – |
| FY2019 | Dec 31, 2019 | -$34.10M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$23.64M | – |
| Q1 FY2026 | Mar 31, 2026 | -$25.13M | – |
| Q4 FY2025 | Dec 31, 2025 | -$20.49M | – |
| Q3 FY2025 | Sep 30, 2025 | -$32.17M | – |
| Q2 FY2025 | Jun 30, 2025 | -$26.02M | – |
| Q1 FY2025 | Mar 31, 2025 | -$26.32M | – |
| Q4 FY2024 | Dec 31, 2024 | -$34.57M | – |
| Q3 FY2024 | Sep 30, 2024 | -$24.67M | – |
| Q2 FY2024 | Jun 30, 2024 | -$17.72M | – |
| Q1 FY2024 | Mar 31, 2024 | -$28.36M | – |
| Q4 FY2023 | Dec 31, 2023 | -$34.75M | – |
| Q3 FY2023 | Sep 30, 2023 | -$27.04M | – |
| Q2 FY2023 | Jun 30, 2023 | -$35.92M | – |
| Q1 FY2023 | Mar 31, 2023 | -$34.78M | – |
| Q4 FY2022 | Dec 31, 2022 | -$37.19M | – |
| Q3 FY2022 | Sep 30, 2022 | -$31.96M | – |
| Q2 FY2022 | Jun 30, 2022 | -$27.41M | – |
| Q1 FY2022 | Mar 31, 2022 | -$31.62M | – |
| Q4 FY2021 | Dec 31, 2021 | -$15.66M | – |
| Q3 FY2021 | Sep 30, 2021 | -$24.68M | – |
| Q2 FY2021 | Jun 30, 2021 | -$22.58M | – |
| Q1 FY2021 | Mar 31, 2021 | -$20.97M | – |
| Q4 FY2020 | Dec 31, 2020 | -$21.80M | – |
| Q3 FY2020 | Sep 30, 2020 | -$21.84M | – |
| Q2 FY2020 | Jun 30, 2020 | -$10.79M | – |
| Q1 FY2020 | Mar 31, 2020 | -$11.91M | – |
| Q4 FY2019 | Dec 31, 2019 | -$10.02M | – |
| Q3 FY2019 | Sep 30, 2019 | -$10.09M | – |
See a number that looks wrong?